MK-0518 [raltegravir] intensification and HDAC [histone deacetylase] inhibition in depletion of resting CD4+ T cell HIV infection.

Trial Profile

MK-0518 [raltegravir] intensification and HDAC [histone deacetylase] inhibition in depletion of resting CD4+ T cell HIV infection.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2011

At a glance

  • Drugs Raltegravir; Valproic acid
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Oct 2011 Actual patient number changed from 7 to 6 as reported by ClinicalTrials.gov.
    • 24 Oct 2011 Actual patient number changed from 7 to 6 as reported by ClinicalTrials.gov.
    • 16 Apr 2010 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov. (NCT00614458).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top